A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Recruiting now · Phase 1/Phase 2

Conditions studied: B-cell Non-Hodgkin Lymphoma

In brief

This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).

Key facts

Study ID

NCT07123454

Run by

AstraZeneca

People needed

91

Starts

2025-09-24

Expected to finish

2028-03-01

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Newcastle upon Tyne, United Kingdom (enrolling)
• Research Site — Jacksonville, Florida, United States (enrolling)
• Research Site — Rochester, Minnesota, United States (enrolling)
• Research Site — New York, New York, United States (enrolling)
• Research Site — New York, New York, United States (enrolling)
• Research Site — Taichung, Taiwan (enrolling)
• Research Site — Taipei, Taiwan (enrolling)
• Research Site — London, United Kingdom (enrolling)
• Research Site — Irvine, California, United States (enrolling)
• Research Site — Franklin, Tennessee, United States (enrolling)
• Research Site — Melbourne, Australia (enrolling)
• Research Site — Bologna, Italy (enrolling)
• Research Site — Milan, Italy (enrolling)
• Research Site — Milan, Italy (enrolling)
• Research Site — Bunkyō City, Japan (enrolling)
• Research Site — Kōtoku, Japan (enrolling)
• Research Site — Seoul, South Korea (enrolling)
• Research Site — Seoul, South Korea (enrolling)
• Research Site — Cleveland, Ohio, United States
• Research Site — Myrtle Beach, South Carolina, United States
• Research Site — Chengdu, China
• Research Site — Guangzhou, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.